NASDAQ:VSTMVerastem Stock Price, Forecast & News

$1.90

+0.04 (+2.42 %)

(As of 06/1/2020 04:00 PM ET)

Add

Compare

Today's Range

$1.82

Now: $1.91▼

$1.94

50-Day Range

$1.73

MA: $2.44▼

$4.20

52-Week Range

$0.83

Now: $1.91▼

$4.67

Volume172,398 shs

Average Volume8.82 million shs

Market Capitalization$309.62 million

P/E RatioN/A

Dividend YieldN/A

Beta1.25

Verastem, Inc., a biopharmaceutical company, focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. The indication in FL is approved under accelerated approval based on overall response rate. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being investigated in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), mesothelioma, and other solid tumors. Verastem, Inc. has collaboration agreements with Yakult Honsha Co., Ltd. and CSPC Pharmaceutical Group Limited. The company was founded in 2010 and is headquartered in Needham, Massachusetts.

Beat the Market (BTM) Rank^™

3.4 Analyst's Opinion

Consensus Rating
Verastem has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $6.00, Verastem has a potential upside of 215.0% from its current price of $1.91.
Amount of Analyst Coverage
Verastem has only been the subject of 2 research reports in the past 90 days.

2.6 Community Rank

Outperform Votes
Verastem has received 560 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Verastem has received 517 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Verastem has received 52.00% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Verastem and other stocks. Vote “Outperform” if you believe VSTM will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VSTM will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Verastem does not currently pay a dividend.
Dividend Growth
Verastem does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Verastem insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $3,006,003.00 in company stock.
Percentage Held by Insiders
Only 2.90% of the stock of Verastem is held by insiders.
Percentage Held by Institutions
50.72% of the stock of Verastem is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Verastem are expected to grow in the coming year, from ($0.76) to ($0.56) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Verastem is -1.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Verastem is -1.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Verastem has a P/B Ratio of 21.17. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.52 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryBiotechnology

SectorMedical

Current SymbolNASDAQ:VSTM

Previous Symbol

CUSIP92337C10

CIK1526119

Webwww.verastem.com

Phone781-292-4200

Debt

Debt-to-Equity Ratio0.48

Current Ratio5.78

Quick Ratio5.61

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$17.46 million

Price / Sales17.73

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.09 per share

Price / Book21.17

Profitability

EPS (Most Recent Fiscal Year)($2.00)

Net Income$-149,210,000.00

Net Margins-715.40%

Return on Equity-282.13%

Return on Assets-74.19%

Miscellaneous

Employees169

Outstanding Shares162,530,000

Market Cap$309.62 million

Next Earnings Date8/6/2020 (Estimated)

OptionableOptionable

Receive VSTM News and Ratings via Email

Sign-up to receive the latest news and ratings for VSTM and its competitors with MarketBeat's FREE daily newsletter.

Verastem (NASDAQ:VSTM) Frequently Asked Questions

How has Verastem's stock been impacted by COVID-19 (Coronavirus)?

Verastem's stock was trading at $2.44 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, VSTM stock has decreased by 21.9% and is now trading at $1.9050. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Verastem?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verastem in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Verastem.

When is Verastem's next earnings date?

Verastem is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Verastem.

How were Verastem's earnings last quarter?

Verastem Inc (NASDAQ:VSTM) announced its earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.35) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.22) by $0.13. The biopharmaceutical company had revenue of $5.06 million for the quarter, compared to the consensus estimate of $3.14 million. Verastem had a negative net margin of 715.40% and a negative return on equity of 282.13%. View Verastem's earnings history.

What price target have analysts set for VSTM?

4 equities research analysts have issued twelve-month price objectives for Verastem's shares. Their forecasts range from $3.00 to $9.00. On average, they expect Verastem's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 215.0% from the stock's current price. View analysts' price targets for Verastem.

Has Verastem been receiving favorable news coverage?

News stories about VSTM stock have been trending somewhat positive this week, InfoTrie reports. The research group scores the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Verastem earned a daily sentiment score of 1.0 on InfoTrie's scale. They also gave news headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutVerastem.

Who are some of Verastem's key competitors?

Some companies that are related to Verastem include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Immunomedics (IMMU). View all competitors.

What other stocks do shareholders of Verastem own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Verastem investors own include TherapeuticsMD (TXMD), Micron Technology (MU), Novavax (NVAX), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX), Amarin (AMRN), Exelixis (EXEL), Synergy Pharmaceuticals (SGYP) and TG Therapeutics (TGTX).

Who are Verastem's key executives?

Verastem's management team includes the following people:

Mr. Robert Forrester, Pres, CEO & Director (Age 55)
Mr. Robert E. Gagnon, Chief Financial Officer (Age 45)
Mr. Joseph M. Lobacki, Exec. VP & Chief Commercial Officer (Age 61)
Mr. Richard H. Aldrich M.B.A., Mba, Founder and Consultant (Age 65)
Dr. Robert A. Weinberg, Co-Founder and Chair of Scientific Advisory Board

What is Verastem's stock symbol?

Verastem trades on the NASDAQ under the ticker symbol "VSTM."

Who are Verastem's major shareholders?

Verastem's stock is owned by a number of institutional and retail investors. Top institutional shareholders include RA Capital Management L.P. (11.45%), Vivo Capital LLC (5.01%), Ikarian Capital LLC (3.23%), VR Adviser LLC (2.29%), BlackRock Inc. (1.05%) and Ghost Tree Capital LLC (0.92%). Company insiders that own Verastem stock include Dan Paterson, Joseph M Lobacki, Michael Kauffman, Ra Capital Management, LP, Robert Forrester, Steven H Bloom and Timothy J Barberich. View institutional ownership trends for Verastem.

Which institutional investors are selling Verastem stock?

VSTM stock was sold by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, BlackRock Inc., Morgan Stanley, Samalin Investment Counsel LLC, UBS Group AG, Howland Capital Management LLC, Howland Capital Management LLC, and Raymond James & Associates. View insider buying and selling activity for Verastem.

Which institutional investors are buying Verastem stock?

VSTM stock was bought by a variety of institutional investors in the last quarter, including RA Capital Management L.P., Vivo Capital LLC, Ikarian Capital LLC, VR Adviser LLC, Ghost Tree Capital LLC, EAM Investors LLC, Matisse Capital, and Telemetry Investments L.L.C.. Company insiders that have bought Verastem stock in the last two years include Dan Paterson, Joseph M Lobacki, Michael Kauffman, Robert Forrester, Steven H Bloom, and Timothy J Barberich. View insider buying and selling activity for Verastem.

How do I buy shares of Verastem?

Shares of VSTM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Verastem's stock price today?

One share of VSTM stock can currently be purchased for approximately $1.91.

How big of a company is Verastem?

Verastem has a market capitalization of $309.62 million and generates $17.46 million in revenue each year. The biopharmaceutical company earns $-149,210,000.00 in net income (profit) each year or ($2.00) on an earnings per share basis. Verastem employs 169 workers across the globe.

What is Verastem's official website?

The official website for Verastem is www.verastem.com.

How can I contact Verastem?

Verastem's mailing address is 117 KENDRICK STREET SUITE 500, NEEDHAM MA, 02494. The biopharmaceutical company can be reached via phone at 781-292-4200 or via email at [email protected]

This page was last updated on 6/1/2020 by MarketBeat.com Staff